ABBV - Ocular Therapeutix: Transformative Year Ahead Full Of Important Milestones

• Blue Sky potential due to potential blockbuster candidates with a differentiated mechanism of action.
• Ocular is working to leverage its proprietary technology platform to optimize drug delivery for additional eye diseases.
• In the second half of the year, the important data release in the multi billion-dollar indication wet-amd is due to take place.
• Current valuation is hedged by increasing revenues from profitable product Dextenza.

For further details see: